1.93
0.04 (2.17%)
| Penutupan Terdahulu | 1.89 |
| Buka | 1.89 |
| Jumlah Dagangan | 408,504 |
| Purata Dagangan (3B) | 1,388,709 |
| Modal Pasaran | 93,282,552 |
| Harga / Pendapatan (P/E Ke hadapan) | 151.52 |
| Harga / Buku (P/B) | 1.15 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2025 - 11 Aug 2025 |
| EPS Cair (TTM) | -1.59 |
| Nisbah Semasa (MRQ) | 9.08 |
| Aliran Tunai Operasi (OCF TTM) | -109.14 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -124.32 M |
| Pulangan Atas Aset (ROA TTM) | -59.03% |
| Pulangan Atas Ekuiti (ROE TTM) | -70.60% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Cassava Sciences, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 0.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | NA |
| AI Insight | NA |
| Purata | -0.33 |
|
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer’s disease dementia. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 12.79% |
| % Dimiliki oleh Institusi | 32.98% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
AI Analisis Teknikal
Buka tab Teknikal untuk menjana analisis terkini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |